EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%

Sezer, A.Kilickap, S.Gumus, M.Bondarenko, I.Ozguroglu, M.Gogishvili, M.Turk, H. M.Cicin, I.Bentsion, D.Gladkov, O.Clingan, P.Sriuranpong, V.Rizvi, N.Li, S.Lee, S.Gullo, G.Lowy, I.Rietschel, P.2021-04-282021-04-2820200923-7534https://www.annalsofoncology.org/article/S0923-7534(20)42367-1/pdfhttp://hdl.handle.net/11727/5789enginfo:eu-repo/semantics/openAccessEMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) >= 50%conferenceObject31S1182S1183000573469102683